LEPU BIO Sets 19 August 2026 Board Meeting to Approve H1 2026 Results and Assess Interim Dividend

Bulletin Express08-07

Lepu Biopharma Co., Ltd. (LEPU BIO) has notified the market that its board of directors will convene on 19 August 2026 in Shanghai. The agenda includes:

• Reviewing and approving the consolidated interim results for the six months ended 30 June 2026. • Considering the declaration of an interim dividend, if any. • Addressing other routine corporate matters.

The notice, signed by Chairman and Executive Director Dr. Pu Zhongjie on 7 August 2026, confirms the current board composition of seven directors: two executive (Dr. Pu Zhongjie and CEO Dr. Sui Ziye), two non-executive (Ms. Pu Jue and Ms. Qin Yiran) and three independent non-executive directors (Mr. Zhou Demin, Mr. Yang Haifeng and Mr. Fengmao Hua).

The forthcoming disclosure of the interim financial statements will provide stakeholders with updated insights into LEPU BIO’s performance during the first half of 2026 and clarify any dividend distribution plans.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1126980317?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 19:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126980317","market":"us","top_or_hot":-1,"title":"LEPU BIO Sets 19 August 2026 Board Meeting to Approve H1 2026 Results and Assess Interim Dividend","media":"Bulletin Express","content":"<p>Lepu Biopharma Co., Ltd. (LEPU BIO) has notified the market that its board of directors will convene on 19 August 2026 in Shanghai. The agenda includes:</p>\n<p>• Reviewing and approving the consolidated interim results for the six months ended 30 June 2026.  \n• Considering the declaration of an interim dividend, if any.  \n• Addressing other routine corporate matters.</p>\n<p>The notice, signed by Chairman and Executive Director Dr. Pu Zhongjie on 7 August 2026, confirms the current board composition of seven directors: two executive (Dr. Pu Zhongjie and CEO Dr. Sui Ziye), two non-executive (Ms. Pu Jue and Ms. Qin Yiran) and three independent non-executive directors (Mr. Zhou Demin, Mr. Yang Haifeng and Mr. Fengmao Hua).</p>\n<p>The forthcoming disclosure of the interim financial statements will provide stakeholders with updated insights into LEPU BIO’s performance during the first half of 2026 and clarify any dividend distribution plans.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LEPU BIO Sets 19 August 2026 Board Meeting to Approve H1 2026 Results and Assess Interim Dividend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLEPU BIO Sets 19 August 2026 Board Meeting to Approve H1 2026 Results and Assess Interim Dividend\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-07 19:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Lepu Biopharma Co., Ltd. (LEPU BIO) has notified the market that its board of directors will convene on 19 August 2026 in Shanghai. The agenda includes:</p>\n<p>• Reviewing and approving the consolidated interim results for the six months ended 30 June 2026.  \n• Considering the declaration of an interim dividend, if any.  \n• Addressing other routine corporate matters.</p>\n<p>The notice, signed by Chairman and Executive Director Dr. Pu Zhongjie on 7 August 2026, confirms the current board composition of seven directors: two executive (Dr. Pu Zhongjie and CEO Dr. Sui Ziye), two non-executive (Ms. Pu Jue and Ms. Qin Yiran) and three independent non-executive directors (Mr. Zhou Demin, Mr. Yang Haifeng and Mr. Fengmao Hua).</p>\n<p>The forthcoming disclosure of the interim financial statements will provide stakeholders with updated insights into LEPU BIO’s performance during the first half of 2026 and clarify any dividend distribution plans.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02157","symbol_name":"乐普生物","start_time":0,"source_url":"","article_id":"1126980317","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126980317","pubTimestamp":1786101936,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Lepu Biopharma Co., Ltd. (LEPU BIO) has notified the market that its board of directors will convene on 19 August 2026 in Shanghai. The agenda includes: • Reviewing and approving the consolidated...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02157":"乐普生物"},"translate_title":"乐普生物定于2026年8月19日召开董事会会议，批准2026年上半年业绩并评估中期股息","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02157":1},"content_text":"Lepu Biopharma Co., Ltd. (LEPU BIO) has notified the market that its board of directors will convene on 19 August 2026 in Shanghai. The agenda includes:\n• Reviewing and approving the consolidated interim results for the six months ended 30 June 2026.  \n• Considering the declaration of an interim dividend, if any.  \n• Addressing other routine corporate matters.\nThe notice, signed by Chairman and Executive Director Dr. Pu Zhongjie on 7 August 2026, confirms the current board composition of seven directors: two executive (Dr. Pu Zhongjie and CEO Dr. Sui Ziye), two non-executive (Ms. Pu Jue and Ms. Qin Yiran) and three independent non-executive directors (Mr. Zhou Demin, Mr. Yang Haifeng and Mr. Fengmao Hua).\nThe forthcoming disclosure of the interim financial statements will provide stakeholders with updated insights into LEPU BIO’s performance during the first half of 2026 and clarify any dividend distribution plans.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1126980317","isCrawlerRequest":true}